MEDICLINIC INTERNATIONAL PLC - Mediclinic half-year results for the six months ended 30 September 2021

Mediclinic half-year results for the six months ended 30 September 2021

Mediclinic International plc
Incorporated in England and Wales
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(“Mediclinic”, or the “Company”, or the “Group”)

MEDICLINIC HALF-YEAR RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021

DELIVERING A STRONG RECOVERY IN FIRST-HALF GROUP OPERATING PERFORMANCE
WITH A RETURN TO PRE-PANDEMIC LEVEL REVENUES AT ALL THREE DIVISIONS

GROUP FINANCIAL RESULTS

    •   Group revenue increased by 12% compared with 1H21 (up 15% in constant currency) driven
        by growth in patient activity; revenue up 4% on pre-pandemic levels (up 11% in constant
        currency)
    •   Group adjusted EBITDA increased by 46% compared with 1H21, driven by revenue growth
        and adjusted EBITDA margin improvement to 15.8% (1H21: 12.1%); adjusted EBITDA
        broadly in line with pre-pandemic levels (up 5% in constant currency compared with 1H20)
    •   Adjusted operating profit of £147m; up 122% on 1H21 and up 2% on pre-pandemic 1H20; in
        constant currency terms up 121% and 8% compared with 1H21 and 1H20, respectively
    •   Operating profit of £129m; up 101% on 1H21 and down 14% on pre-pandemic 1H20
    •   Adjusted earnings and adjusted earnings per share significantly increased compared with the
        prior year period and 10% up on pre-pandemic period
    •   Reported earnings and reported earnings per share both up 330% to £65m (1H21: £15m) and
        8.8 pence (1H21: 2.0 pence), respectively
    •   Headline earnings per share 8.8 pence (1H21: 2.4 pence)
    •   Net incurred debt continues to reduce, down £269m compared with the prior period and
        £349m compared with pre-pandemic period
    •   Liquidity position strengthened to £770m of cash and available facilities compared with
        £679m at FY21; supported by recovery in operating performance and strong Group cash
        conversion of 104% (1H21: 42%; FY21: 77%)
    •   Dividend remains suspended as part of the Group's broad response to maintaining its liquidity
        position

FURTHER INFORMATION
The contents of this short-form announcement is the responsibility of the Board of Directors of the
Company. This announcement represents a summary of the information contained in the unabridged
results announcement. Any investment decisions by investors and/or shareholders should be based
on a consideration of the unabridged announcement. The unabridged announcement can be
accessed on the following JSE link:

https://senspdf.jse.co.za/documents/2021/JSE/ISSE/MEIE/MEIHY22.pdf

The announcement is also published on www.mediclinic.com and available for inspection at the
registered office of the Company and the offices of the Company’s sponsor at no charge, during
normal business hours.

CORPORATE INFORMATION

LISTINGS
The Company’s primary listing is on the London Stock Exchange in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

DIRECTORS
Inga Beale DBE (ind ne) (Chair) (British), Dr Ronnie van der Merwe (Group Chief Executive Officer)
(South African), Jurgens Myburgh (Group Chief Financial Officer) (South African), Dr Felicity Harvey
CBE (Senior Independent Director) (British), Dr Muhadditha Al Hashimi (ind ne) (Emirati), Natalia
Barsegiyan (ind ne) (French and Russian), Jannie Durand (ne) (South African), Alan Grieve (ind ne)
(British and Swiss), Danie Meintjes (ne) (South African), Dr Anja Oswald (ind ne) (Swiss), Trevor
Petersen (ind ne) (South African), Tom Singer (ind ne) (British), Steve Weiner (ind ne) (American),
Pieter Uys (alternate to Jannie Durand) (South African)

COMPANY SECRETARY
Link Company Matters Limited (previously named Capita Company Secretarial Services Limited)

REGISTERED OFFICE
Mediclinic International plc
6th Floor, 65 Gresham Street
London, EC2V 7NQ, United Kingdom
Tel: +44 333 300 1930
Email: info@mediclinic.com
Website: www.mediclinic.com

TOLL-FREE ETHICS LINES AND EMAIL
Switzerland
Tel: 0800 005 316
South Africa
Tel: 0800 005 316
MTC Networks: 081 91847
Namibia
Tel: 0800 003 313
The United Arab Emirates
Tel: 800 1 55000

Email: mediclinic@tip-offs.com

REGISTRAR/TRANSFER SECRETARIES
UK
United Kingdom Computershare Investor Services PLC
SOUTH AFRICA
Computershare Investor Services (Pty) Ltd
NAMIBIA
Transfer Secretaries (Pty) Ltd

CORPORATE ADVISORS

AUDITOR
PricewaterhouseCoopers LLP, London

CORPORATE BROKER AND SPONSORS
UK
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
South Africa
JSE sponsor: Rand Merchant Bank (a division of FirstRand Bank Limited)
Namibia
NSX sponsor: Simonis Storm Securities (Pty) Ltd

11 November 2021



Date: 11-11-2021 09:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.